经内镜逆行胰胆管造影术后胰腺炎的研究进展

摘要
图/表
参考文献(73)
相关文章 (15)

全文: PDF (0 KB) HTML (66 KB)
输出: BibTeX | EndNote (RIS)

摘要经内镜逆行胰胆管造影术后胰腺炎（PEP）是经内镜逆行胰胆管造影术（ERCP）后最常见的并发症之一，PEP 通常是轻度或中度的，然而有些病例可能发展为严重的胰腺炎，导致患者的健康和生命受到严重伤害。目前PEP 的危险因素众多，且缺乏标准、有效的预防措施以降低其发生率。本研究纳入30 余项国内外近期关于PEP的研究，发现PEP 有复杂的病理生理机制，并有众多的危险因素，包括患者因素以及与手术相关的因素，随着研究的进展，目前需要消除对某些传统危险因素的偏见；在预防方面，内镜下的预防和药物预防均有一定的效果，但尚未完全规范化。本研究将在现有研究基础上，对PEP 的发病机制、危险因素、预防措施、临床表现及治疗作一综述，旨在进一步提高ERCP 诊治水平和安全性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王祥瑞
	宁波

关键词 ：经内镜逆行胰胆管造影, 经内镜逆行胰胆管造影术后胰腺炎, 危险因素, 预防

Abstract：Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is one of the most common complications after post-endoscopic retrograde cholangiopancreatography pancreatitis (ERCP). PEP is usually mild or moderate, however, some cases may develop into severe pancreatitis, resulting in serious harm to patient's health and life.Currently, there are many risk factors for PEP and a lack of standard, effective prevention to reduce its incidence. This research included more than 30 recent domestic and international studies on PEP and finds that PEP has complex pathophysiological mechanisms and numerous risk factors,including patient-related factors and procedure-related factors.With the progress of research, there is an ongoing need to remove the bias against certain traditional risk factors. In terms of prevention, both endoscopic and pharmacological prevention have been effective but it is not fully normalized yet. Basing on existing studies, this research will review the pathogenesis, risk factors, prevention, clinical manifestations and treatment of PEP. It aims to improve the level of diagnosis and treatment and the safety of ERCP.

Key words： Endoscopic retrograde cholangiopancreatography Post-endoscopic retrograde cholangiopancreatography pancreatitis Risk factors Prevention

基金资助:重庆市卫生和计划生育委员会医学科研计划项目（2016HBRC003）。

通讯作者: 宁波（1976-），男，重庆人，博士，副主任医师，副教授，硕士研究生导师，研究方向：胆胰疾病的内镜下治疗、非酒精性脂肪性肝病的诊治。

作者简介: 王祥瑞（1995-），女，湖北襄阳人，硕士，研究方向：胆胰疾病的内镜下治疗

引用本文:

王祥瑞；宁波. 经内镜逆行胰胆管造影术后胰腺炎的研究进展[J]. 中国当代医药, 2021, 28(30): 33-39.
WANG Xiang-rui；NING Bo. Research progress of post-endoscopic retrograde cholangiopancreatography pancreatitis. 中国当代医药, 2021, 28(30): 33-39.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I30/33

[1]	陈文华，林军，王剑屏，等.ERCP 术后胰腺炎的危险因素及预防措施[J].国际消化病杂志，2018，38（2）：79-83.
[2]	Cheon YK，Cho KB，Watkins JL，et al.Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacifification[J].Gastrointest Endosc，2007，65（3）：385-393.
[3]	Cotton PB，Garrow DA，Gallagher J，et al.Risk factors for complications after ERCP：a multivariate analysis of 11497 procedures over 12 years[J].Gastrointest Endosc，2009，70（1）：80-88.
[4]	Andriulli A，Loperfifido S，Napolitano G，et al.Incidence rates of post-ERCP complications：a systematic survey of prospective studies[J].Am J Gastroenterol，2007，102（8）：1781-1788.
[5]	Barthet M，Lesavre N，Desjeux A，et al.Complications of endoscopic sphincterotomy：results from a single tertiary referral center[J].Endoscopy，2002，34（12）：991-997.
[6]	Dumonceau JM，Andriulli A，Elmunzer BJ，et al.Prophylaxis of post-ERCP pancreatitis：European Society of Gastrointestinal Endoscopy （ESGE）Guideline-updated June 2014[J].Endoscopy，2014，46（9）：799-815.
[7]	ASGE Standards of Practice Committee，Chandrasekhara V，Khashab MA，et al.Adverse events associated with ERCP[J].Gastrointest Endosc，2017，85（1）：32-47.
[8]	Feurer ME，Adler DG.Post-ERCP pancreatitis：review of current preventive strategies[J].Curr Opin Gastroenterol，2012，28（3）：280-286.
[9]	ASGE Standards of Practice Committee，Anderson MA，Fisher L，et al.Complications of ERCP[J].Gastrointest Endosc，2012，75（3）：467-473.
[10]	Boskoski I，Costamagna G.How to Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis[J].Gastroenterology，2020，158（8）：2037-2040.
[11]	Funatsu E，Masuda A，Takenaka M，et al.History of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Acute Pancreatitis as Risk Factors for Post ERCP Pancreatitis[J].Kobe J Med Sci，2017，63（1）：E1-E8.
[12]	Johnson GK，Geenen JE，Johanson JF，et al.Evaluation of post-ERCP pancreatitis：potential causes noted during controlled study of differing contrast media.Midwest Pancreaticobiliary Study Group[J].Gastrointest Endosc，1997，46（3）：217-222.
[13]	Proenca IM，dos Santos MEL，de Moura DTH，et al.Role of pancreatography in the endoscopic management of encapsulated pancreatic collections-review and new proposed classification[J].World J Gastroenterol，2020，26（45）：7104-7117.
[14]	George S，Kulkarni AA，Stevens G，et al.Role of osmolality of contrast media in the development of post-ERCP pancreatitis：a metanalysis[J].Dig Dis Sci，2004，49（3）：503-508.
[15]	Sherman S，Hawes RH，Troiano FP，et al.Pancreatitis following bile duct sphincter of Oddi manometry：utility of the aspirating catheter[J].Gastrointest Endosc，1992，38（3）：347-350.
[16]	Pezzilli R，Romboli E，Campana D，et al.Mechanisms involved in the onset of post-ERCP pancreatitis[J].JOP，2002，3（6）：162-168.
[17]	Szary NM，Al-kawas FH.Complications of endoscopic retrograde cholangiopancreatography：how to avoid and manage them[J].Gastroenterol Hepatol （NY），2013，9（8）：496-504.
[18]	Freeman ML.Adverse outcomes of ERCP [J].Gastrointest Endosc，2002，56（6）：273-282.
[19]	Lerch MM，Saluja AK，Rünzi M，et al.Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum[J].Gastroenterology，1993，104（3）：853-861.
[20]	Ohshio G，Saluja A，Steer ML.Effects of short-term pancreatic duct obstruction in rats[J].Gastroenterology，1991，100（1）：196-202.
[21]	Crockett SD，Wani S，Gardner TB，et al.American Gastroenterological Association Institute Clinical Guidelines Committee.American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis[J].Gastroenterology，2018，154（4）：1096-1101.
[22]	Tenner S，Baillie J，DeWitt J，et al.American College of Gastroenterology.American College of Gastroenterology guideline：management of acute pancreatitis[J].Am J Gastroenterol，2013，108（9）：1400-1416.
[23]	Swaroop VS，Chari ST，Clain JE.Severe acute pancreatitis[J].JAMA，2004，291（23）：2865-2868.
[24]	Lee PJ，Papachristou GI.Management of Severe Acute Pancreatitis[J].Curr Treat Options Gastroenterol，2020，18（3）：1-12.
[25]	Basurto Ona X，Rigau Comas D，Urrútia G.Opioids for acute pancreatitis pain[J].Cochrane Database Syst Rev，2013，26（7）：1-48.
[26]	Mederos MA，Reber HA，Girgis MD.Acute Pancreatitis：A Review[J].JAMA，2021，325（23）：382-390.
[33]	Iorgulescu A，Sandu I，Turcu F.Post-ERCP acute pancreatitis and its risk factors[J].J Med Life，2013，6（1）：109-113.
[34]	Chen J，Wang X，Liu X，et al.Risk factors for Post-ERCP pancreatitis：a systematic[J].Eur J Med Res，2014，19（26）：1-7.
[27]	Messallam AA，Body CB，Berger S，et al.Impact of early aggressive fluid resuscitation in acute pancreatitis[J].Pancreatology，2021，21（1）：69-73.
[28]	Zhang J，Zhu S，Tan D，et al.A meta-analysis of early oral refeeding and quickly increased diet for patients with mild acute pancreatitis[J].Saudi J Gastroenterol，2019，25（1）：14-19.
[29]	Lella F，Bagnolo F，Colombo E，et al.A simple way of avoiding post-ERCP pancreatitis[J].Gastrointest Endosc，2004，59（7）：830-834.
[30]	Freeman ML，Disario JA，Nelson DB，et al.Risk factors for post-ERCP pancreatitis：a prospective，multicenter study[J].Gastrointest Endosc，2001，54（4）：425-434.
[31]	Freeman ML，Nelson DB，Sherman S，et al.Complications of endoscopic biliary sphincterotomy[J].N Engl J Med，1996，335（13）：909-918.
[32]	Trap R，Adamsen S，Hart-hansen O，et al.Severe and fatal complications after diagnostic and therapeutic ERCP：a prospective series of claims to insurance covering public hospitals[J].Endoscopy，1999，31（2）：125-130.
[35]	DeBenedet AT，Raghunathan TE，Wing JJ，et al.Alcoholuse and cigarette smoking as risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis[J].Clin Gastroenterol Hepatol，2009，7（3）：353-358.
[36]	Dumonceau JM，Kapral C，Aabakken L，et al.ERCP-related adverse events：European Society of Gastrointestinal Endoscopy （ESGE） Guideline[J].Endoscopy，2020，52（2）：127-149.
[37]	Ding X，Zhang F，Wang Y.Risk factors for post-ERCP pancreatitis：a systematic review and meta-analysis[J].Surgeon，2015，13（4）：218-229.
[38]	Matsubayashi CO，Ribeiro IB，de Moura DTH，et al.Is Endoscopic Balloon Dilation Still Associated With Higher Rates of Pancreatitis?[J].Pancreas，2020，49（2）：158-174.
[39]	Mouri T，Sasaki T，Serikawa M，et al.A comparison of 4Fr with 5Fr endoscopic nasopancreatic drainage catheters：A randomized，controlled trial[J].J Gastroenterol Hepatol，2016，31（10）：1783-1780.
[40]	Kang X，Zheng L，Zeng W，et al.Risk Factors for Post-ERCP Pancreatitis in High-Risk Patients Receiving Post-procedure Rectal Indomethacin[J].J Gastrointest Surg，2018，22（11）：1903-1910.
[41]	Loperfifido S，Angelini G，Benedetti G，et al.Major early complications from diagnostic and therapeutic ERCP：a prospective multicenter study[J].Gastrointest Endosc，1998，48（1）：1-10.
[42]	Rabenstein T，Schneider HT，Bulling D，et al.Analysis of the risk factors associated with endoscopic sphincterotomy techniques：preliminary results of a prospective study，with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment[J].Endoscopy，2000，32（1）：10-19.
[43]	Coté GA，Kumar N，Ansstas M，et al.Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents[J].Gastrointest Endosc，2010，72（4）：748-754.
[44]	Wang P，Li ZS，Liu F，et al.Risk factors for ERCP-related complications：a prospective multicenter study[J].Am J Gastroenterol，2009，104（1）：31-40.
[45]	Pan Y，Zhao L，Leung J，et al.Appropriate time for selective biliary cannulation by trainees during ERCP—a randomized trial[J].Endoscopy，2015，47（8）：688-695.
[46]	Morales SJ，Sampath K，Gardner TB.A Review of Prevention of Post-ERCP Pancreatitis[J].Gastroenterol Hepatol（NY），2018，14（5）：286-292.
[47]	Syrén E，Eriksson S，Enochsson L，et al.Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography[J].BJS Open，2019，3（4）：485-489.
[48]	Artifon EL，Sakai P，Cunha JE，et al.Guidewire cannulation reduces risk of post-ERCP pancreatitis and facilitates bile duct cannulation[J].Am J Gastroenterol，2007，102（10）：2147-2153.
[49]	Bailey AA，Bourke MJ，Williams SJ，et al.A prospective randomized trial of cannulation technique in ERCP：effects on technical success and post-ERCP pancreatitis[J].Endoscopy，2008，40（4）：296-301.
[50]	Testoni PA，Mariani A，Aabakken L，et al.Papillary cannulation and sphincterotomy techniques at ERCP：European Society of Gastrointestinal Endoscopy （ESGE） Clinical Guideline[J].Endoscopy，2016，48（7）：657-683.
[51]	Tse F，Yuan Y，Moayyedi P，et al.Guide wire-assisted cannulation for the prevention of post-ERCP pancreatitis：a systematic review and meta-analysis[J].Endoscopy，2013，45（8）：605-618.
[52]	Sasahira N，Kawakami H，Isayama H，et al.Early use of double guidewire technique to facilitate selective bile duct cannulation：the multicenter randomized controlled EDUCATION trial[J].Endoscopy，2015，47（5）：421-429.
[53]	Madácsy L，Kurucsai G，Joó I，et al.Rescue ERCP and insertion of a smallcaliber pancreatic stent to prevent the evolution of severe post-ERCP pancreatitis：a case-controlled series[J].Surg Endosc，2009，23（8）：1887-1893.
[54]	Funari MP，Ribeiro IB，de Moura DTH，et al.Adverse events after biliary sphincterotomy：Does the electric current mode make a difference?[J].Clin Res Hepatol Gastroenterol，2020，44（5）：739-752.
[55]	Maharshi S，Sharma SS.Early precut versus primary precut sphincterotomy to reduce post-ERCP pancreatitis：randomized controlled trial[J].Gastrointest Endosc，2021，93（3）：586-593.
[56]	Kerdsirichairat T，Attam R，Arain M，et al.Urgent ERCP with pancreatic stent placement or replacement for salvage of post-ERCP pancreatitis[J].Endoscopy，2014，46（12）：1085-1094.
[57]	Karjula H，Nordblad Schmidt P，Makela J，et al.Prophylactic pancreatic duct stenting in severe acute necrotizing pancreatitis：a prospective randomized study[J].Endoscopy，2019，51（11）：1027-1034.
[58]	Shaygan-Nejad A，Masjedizadeh AR，Ghavidel A，et al.Aggressive hydration with Lactated Ringer's solution as the prophylactic intervention for postendoscopic retrograde cholangiopancreatography pancreatitis：A randomized controlled double-blind clinical trial[J].J Res Med Sci，2015，20（9）：838-843.
[59]	Vadalà di Prampero SF，Faleschini G，Panic N，et al.Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis：a meta-analysis and systematic review[J].Eur J Gastroenterol Hepatol，2016，28（12）：1415-1424.
[60]	Akbar A，Abu Dayyeh BK，Baron TH，et al.Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography：a network meta-analysis[J].Clin Gastroenterol Hepatol，2013，11（7）：778-783.
[61]	Ishiwatari H，Urata T，Yasuda I，et al.No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis[J].Dig Dis Sci，2016，61（11）：3292-3301.
[62]	Iqbal U，Siddique O，Khara HS，et al.Post-endoscopic retrograde cholangiopancreatography pancreatitis prevention using topical epinephrine：systematic review and metaanalysis[J].Endosc Int Open，2020，8（8）：1061-1067.
[63]	Chen B，Fan T，Wang CH.A meta-analysis for the effect of prophylactic GTN on the incidence of post-ERCP pancreatitis and on the successful rate of cannulation of bile ducts[J].BMC Gastroenterol，2010，10：85.
[64]	Sotoudehmanesh R，Eloubeidi MA，Asgari AA，et al.A randomized trial of rectal indomethacin and sublingual nitrates to prevent post-ERCP pancreatitis[J].Am J Gastroenterol，2014，109（6）：903-909.
[65]	Tomoda T，Kato H，Ueki T，et al.Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography[J].Gastroenterology，2019，156（6）：1753-1760.
[66]	Andriulli A，Leandro G，Federici T，et al.Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP：an updated meta-analysis[J].Gastrointest Endosc，2007，65（4）：624-632.
[67]	Qin X，Lei WS，Xing ZX，et al.Prophylactic effect of somatostatin in preventing Post-ERCP pancreatitis：an updated meta-analysis[J].Saudi J Gastroenterol，2015，21（6）：372-378.
[68]	Bai Y，Gao J，Zou DW，et al.Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis：a meta-analysis of randomized controlled trials[J].Pancreas，2008，37（3）：241-246.
[69]	Omata F，Deshpande G，Tokuda Y，et al.Meta-analysis：somatostatin or its long-acting analogue，octreotide，for prophylaxis against post-ERCP pancreatitis[J].J Gastroenterol，2010，45（8）：885-895.
[70]	Seta T，Noguchi Y.Protease inhibitors for preventing complications associated with ERCP：an updated meta-analysis[J].Gastrointest Endosc，2011，73（4）：700-706.
[71]	Yu G，Li S，Wan R，et al.Nafamostat mesilate for prevention of post-ERCP pancreatitis：a meta-analysis of prospective，randomized，controlled trials[J].Pancreas，2015，44（4）：561-569.
[72]	Yuhara H，Ogawa M，Kawaguchi Y，et al.Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis：protease inhibitors and NSAIDs in a meta-analysis[J].J Gastroenterol，2014，49（3）：388-399.
[73]	Chen S，Shi H，Zou X，et al.Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis：the Emperor's New Clothes or Aladdin's Magic Lamp?[J].Pancreas，2010，39（8）：1231-1237.